Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 6/20 | 0.37 |
| ▸ | SLC16A1 | P53985 | 6/20 | 0.37 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012799 | 0.89 | HTR2C (0.49) | HTR2CSLC6A4HTR2ASLC16A3SLC16A1 | |
| SCHEMBL2838656 | 0.85 | ALDH1A1 (0.39) | SLC16A3SLC16A1ALDH1A1GRNSORT1 | |
| SCHEMBL2837803 | 0.80 | HTR2C (0.52) | HTR2CSLC6A4SLC16A3SLC16A1MCTS1 | |
| SCHEMBL2838918 | 0.73 | NPSR1 (0.37) | SLC16A3SLC16A1ALDH1A1CNR1CNR2 | |
| SCHEMBL10080842 | 0.72 | HTR2C (0.67) | HTR2CSLC6A4HTR2ASLC16A3SLC16A1 | |
| SCHEMBL14924172 | 0.72 | HTR2C (0.72) | HTR2CSLC6A4HTR2ASLC16A3SLC16A1 | |
| Hydrochloric Acid SCHEMBL2841112 | 0.70 | MEN1 (0.43) | HTR2CSLC6A4HTR2ACNR1CNR2 | |
| SCHEMBL10080825 | 0.69 | HTR2C (0.67) | HTR2CSLC6A4HTR2ASLC16A3SLC16A1 | |
| SCHEMBL24035183 | 0.69 | ALDH1A1 (0.40) | HTR2CSLC6A4ALDH1A1GRNSORT1 | |
| SCHEMBL7190668 | 0.68 | RIPK1 (0.57) | HTR2CSLC6A4GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3162798-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
| EP-2196459-B1 | 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-8334301-B2 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20100210696-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2196459-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210696-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND | NPY4R, NPY5R, NPY1R | HTR2C 1425/4885SLC6A4 1108/4885HTR2A 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.